Back to top
more

Ecolab (ECL)

(Delayed Data from NYSE)

$244.57 USD

244.57
1,399,786

-1.16 (-0.47%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $244.55 -0.02 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 43% (142 out of 250)

Industry: Chemical - Specialty

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

QuidelOrtho (QDEL) Q1 Earnings Beat Estimates, Margins Fall

by Zacks Equity Research

QuidelOrtho's (QDEL) first-quarter results reflect growth in revenues, excluding the COVID-19 revenue impact.

Ashland (ASH) to Divest Nutraceuticals Business to Turnspire

by Zacks Equity Research

Ashland (ASH) is set to sell its nutraceuticals business to Turnspire Capital Partners, with the deal expected to close in third-quarter 2024.

OPKO Health's (OPK) Q1 Earnings Miss Estimates, Sales Down Y/Y

by Zacks Equity Research

OPKO Health's (OPK) first-quarter results reflect soft performances despite robust RAYALDEE sales and strength in the Pharmaceuticals segment.

Should You Invest in the Invesco Water Resources ETF (PHO)?

by Zacks Equity Research

Sector ETF report for PHO

McKesson (MCK) Q4 Earnings Miss Estimates, Revenues Up Y/Y

by Zacks Equity Research

McKesson's (MCK) fourth-quarter fiscal 2024 results showcase growth in the U.S. Pharmaceutical while lower COVID-related sales hurt the Medical Surgical Solutions segment.

Nevro's (NVRO) Q1 Earnings and Sales Beat Estimates, Margins Up

by Zacks Equity Research

Nevro's (NVRO) first-quarter earnings and revenues surpass their respective Zacks Consensus Estimate. The company incurs a loss in the operating level.

Masimo (MASI) Q1 Earnings Beat Estimates, '24 EPS View Up

by Zacks Equity Research

Masimo's (MASI) Q1 healthcare revenues reflect strong sensor orders, which were completely offset by lower capital equipment purchases. Sensor production in Malaysia is likely to improve Healthcare gross margin.

Fresenius Medical (FMS) Q1 Earnings Beat, Operating Margin Up

by Zacks Equity Research

Fresenius Medical's (FMS) first-quarter revenues suffer due to unfavorable currency movement. However, the company's transformational plans continue to benefit its operating income.

Barrick (GOLD) Announces Partnership With Geophysx Jamaica

by Zacks Equity Research

The agreement initially grants Barrick (GOLD) access to about 4,000 square kilometers of consolidated land positions across the country.

DOW to Sell Flexible Packaging Laminating Adhesives Business

by Zacks Equity Research

This deal allows DOW to focus even more on core, high-value downstream operations.

Are You Looking for a Top Momentum Pick? Why Ecolab (ECL) is a Great Choice

by Zacks Equity Research

Does Ecolab (ECL) have what it takes to be a top stock pick for momentum investors? Let's find out.

Quest Diagnostics (DGX) Grows in Digital Pathology With New Deal

by Zacks Equity Research

Quest Diagnostics' (DGX) pathology laboratories nationwide are set to get a boost with PathAI's AISight digital pathology image management system.

Shockwave Medical (SWAV) Q1 Earnings Beat, Revenues Rise Y/Y

by Zacks Equity Research

Shockwave Medical's (SWAV) first-quarter results reflect robust revenue growth and gross margin expansion amid JNJ entering into a definitive agreement to acquire the company.

GE HealthCare (GEHC) Unveils Head-Only MR Scanner SIGNA MAGNUS

by Zacks Equity Research

GE HealthCare's (GEHC) new SIGNA MAGNUS can delve deep into the brain's microstructure, microvasculature and function, providing researchers with a clearer picture of neurological diseases and disorders.

Should You Invest in the First Trust Water ETF (FIW)?

by Zacks Equity Research

Sector ETF report for FIW

Avanos (AVNS) Q1 Earnings & Revenues Surpass Estimates

by Zacks Equity Research

Avanos' (AVNS) first-quarter results show strong bottom-line improvement along with decent growth in segmental revenues.

Surmodics (SRDX) Q2 Earnings Top Estimates, '24 View Up

by Zacks Equity Research

Surmodics (SRDX) fiscal second-quarter results showcase growth in the medical device segment. The bottom line improves and beats the Zacks Consensus Estimate.

GE Healthcare's (GEHC) Revolution RT to Aid Cancer Treatment

by Zacks Equity Research

GE Healthcare (GEHC) unveils Revolution RT, along with other upgrades, from its portfolio during the ESTRO 2024 Congress.

Here's Why Ecolab (ECL) is a Strong Momentum Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

DENTSPLY SIRONA (XRAY) Q1 Earnings In Line, Revenues Decline Y/Y

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) first-quarter 2024 results showcase a decline in year-over-year sales with an improved bottom line.

Cardinal Health (CAH) Beats on Q3 Earnings, Ups '24 EPS View

by Zacks Equity Research

Cardinal Health's (CAH) third-quarter fiscal 2024 results benefit from solid profit growth in Pharmaceutical and Specialty Solutions. The company raises its EPS guidance for fiscal 2024.

Baxter (BAX) Q1 Earnings Beat Estimates, '24 EPS View Raised

by Zacks Equity Research

Baxter (BAX) reports better-than-expected first-quarter earnings and sales. BAX's quarterly results reflect solid demand for a range of its medically essential products.

Glaukos (GKOS) Q1 Earnings Miss Estimates, Revenues Up Y/Y

by Zacks Equity Research

Glaukos' (GKOS) first-quarter 2024 results showcase growth in revenues while earnings miss the Zacks consensus Estimate. Loss at the operating level raises concern as well.

Inari Medical (NARI) Q1 Earnings Miss Estimates, OpEx Rises

by Zacks Equity Research

Inari Medical's (NARI) first-quarter results witness an increase in revenues with dismal bottom-line performance. Gross margins contract while the companies continue to incur operating losses.

Here's Why Ecolab (ECL) is a Strong Growth Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.